黄葵胶囊联合达格列净对早期糖尿病肾病患者Cys-C、α1-MG的影响  

Effect of Huangkui capsule combined with dapagliflozin on Cys-C and α1-MG in patients with early diabetic nephropathy

作　　者：杨德玉[1] 岑俊[1] 罗茜 陈灵烜 顾谊铮[1] YANG De-yu;CEN Jun;LUO Xi(Department of Nephrology,Shanghai Construction Engineering Hospital,Shanghai 200083,China)

机构地区：[1]上海建工医院肾内科,200083 [2]南方医科大学检验与生物技术学院,510515 [3]南方医科大学第一临床医学院

出　　处：《中国现代药物应用》2023年第10期29-33,共5页Chinese Journal of Modern Drug Application

摘　　要：目的 探究黄葵胶囊联合达格列净对早期糖尿病肾病患者胱抑素C(Cys-C)、α1-微球蛋白(α1-MG)的影响。方法 115例早期糖尿病肾病患者,依据随机数字表法将其分为达格列净组(35例)、黄葵胶囊组(38例)、联合组(42例)。达格列净组给予达格列净治疗,黄葵胶囊组给予黄葵胶囊治疗,联合组给予黄葵胶囊联合达格列净治疗。对比三组治疗前后血糖[空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)]、炎性因子[可溶性细胞间黏附分子1(sICAM-1)、高迁移率族蛋白B1(HMGB1)、单核细胞趋化蛋白1(MCP-1)]、胱抑素C(Cys-C)、α1-微球蛋白(α1-MG)水平。结果 治疗后,达格列净组FBG为(6.79±0.96)mmol/L、2 h PG为(10.12±2.07)mmol/L、HbA1c为(7.03±1.02)%;黄葵胶囊组FBG为(6.64±0.91)mmol/L、2 h PG为(9.34±1.96)mmol/L、HbA1c为(6.71±0.94)%;联合组FBG为(5.60±0.76)mmol/L、2 h PG为(5.65±1.13)mmol/L、HbA1c为(6.03±0.62)%。治疗后,三组FBG、2 h PG、HbA1c水平均低于本组治疗前,且联合组FBG、2 h PG、HbA1c水平均低于达格列净组与黄葵胶囊组,差异均有统计学意义(P<0.05)。治疗后,达格列净组s ICAM-1为(168.94±24.74)μg/L、HMGB1为(10.39±1.95)μg/L、MCP-1为(155.49±14.50)ng/L;黄葵胶囊组s ICAM-1为(153.28±23.11)μg/L、HMGB1为(9.41±1.84)μg/L、MCP-1为(146.23±13.73)ng/L;联合组sICAM-1为(102.38±22.74)μg/L、HMGB1为(5.20±1.25)μg/L、MCP-1为(132.87±15.75)ng/L。治疗后,三组sICAM-1、HMGB1、MCP-1水平均低于本组治疗前,且联合组s ICAM-1、HMGB1、MCP-1水平均低于达格列净组与黄葵胶囊组,差异均有统计学意义(P<0.05)。治疗后,达格列净组Cys-C为(2.03±0.48)mg/L、尿α1-MG为(13.45±2.16)mg/L;黄葵胶囊组Cys-C为(1.92±0.51)mg/L、尿α1-MG为(12.67±2.01)mg/L;联合组Cys-C为(1.06±0.35)mg/L、尿α1-MG为(8.42±1.73)mg/L。治疗后,三组Cys-C、尿α1-MG水平均低于本组治疗前,且联合组Cys-C、尿α1-MG水平均低于达格列净组与黄葵胶囊Objective To investigate the effect of Huangkui capsule combined with dapagliflozin on cystatin C(Cys-C)andα1-microglobulin(α1-MG)in patients with early diabetic nephropathy.Methods A total of 115 patients with early diabetic nephropathy were divided into dapagliflozin group(35 cases),Huangkui capsule group(38 cases),combined group(42 cases)according to random numerical table.The dapagliflozin group was treated with dapagliflozin,the Huangkui capsule group was treated with Huangkui capsule,and the combined group was treated with Huangkui capsule and dapagliflozin.Both groups were compared in terms of blood glucose[fasting blood glucose(FBG),2 h postmortem glucose(2 h PG),glycosylated hemoglobin(HbA1c)],inflammatory factors[soluble intercellular adhesion molecule-1(sICAM-1),high mobility group protein B1(HMGB1),monocyte chemotactic protein-1(MCP-1)]and cystatin C(Cys-C),α1-microglobulin(α1-MG)levels.Results After treatment,dapagliflozin group had FBG of(6.79±0.96)mmol/L,2 h PG of(10.12±2.07)mmol/L,and HbA1c of(7.03±1.02)%;Huangkui capsule group had FBG of(6.64±0.91)mmol/L,2 h PG of(9.34±1.96)mmol/L,HbA1c of(6.71±0.94)%;combined group had FBG of(5.60±0.76)mmol/L,2 h PG of(5.65±1.13)mmol/L,HbA1c of(6.03±0.62)%.After treatment,the levels of FBG,2 h PG and HbA1c in the three groups were lower than those before treatment in this group;the levels of FBG,2 h PG and HbA1c in the combined group were lower than those in dapagliflozin group and Huangkui capsule group;the differences were statistically significant(P<0.05).After treatment,dapagliflozin group had sICAM-1 of(168.94±24.74)μg/L,HMGB1 of(10.39±1.95)μg/L,MCP-1 of(155.49±14.50)ng/L;Huangkui capsule group had sICAM-1 of(153.28±23.11)μg/L,HMGB1 of(9.41±1.84)μg/L,MCP-1 of(146.23±13.73)ng/L;combined group had sICAM-1 of(102.38±22.74)μg/L,HMGB1 of(5.20±1.25)μg/L,MCP-1 of(132.87±15.75)ng/L.After treatment,the levels of sICAM-1,HMGB1 and MCP-1 in the three groups were lower than those before treatment in this group;the levels of sICAM-1,HMGB1 and

关 键 词：早期糖尿病肾病 黄葵胶囊 达格列净 血清胱抑素C Α1-微球蛋白 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]